SCHEMBL3139569

SCHEMBL3139569

O=C(O)CCCC(=O)Nc1ccc(F)cc1

nearest known ligand 0.80

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.70
ALDH1A1 P00352 1/20 0.70
KMT2A Q03164 3/20 0.69
MEN1 O00255 2/20 0.69
HDAC3 O15379 2/20 0.68
HDAC1 Q13547 2/20 0.68
HDAC2 Q92769 2/20 0.68
HDAC6 Q9UBN7 2/20 0.68
MAPT P10636 1/20 0.62
FOLH1 Q04609 1/20 0.62
GAA P10253 3/20 0.59
L3MBTL1 Q9Y468 2/20 0.59
NPSR1 Q6W5P4 1/20 0.59
HSD17B10 Q99714 1/20 0.59
CYP1A1 P04798 1/20 0.56
LMNA P02545 1/20 0.55
MAPK1 P28482 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28804407 0.96 HDAC1 (0.73) POLBALDH1A1KMT2AMEN1HDAC3
SCHEMBL3234328 0.95 HDAC1 (0.76) POLBALDH1A1KMT2AMEN1HDAC3
SCHEMBL7107371 0.91 POLB (0.82) POLBALDH1A1KMT2AMEN1HDAC3
SCHEMBL7095470 0.89 CYP1A1 (0.70) POLBALDH1A1KMT2AMEN1HDAC3
SCHEMBL3152473 0.84 CYP1A1 (0.79) POLBALDH1A1KMT2AMEN1MAPT
SCHEMBL3806017 0.83 MEN1 (0.73) POLBALDH1A1KMT2AMEN1HDAC3
SCHEMBL24040103 0.82 POLB (0.70) POLBALDH1A1KMT2AMEN1HDAC3
SCHEMBL8652127 0.82 POLB (0.70) POLBALDH1A1KMT2AMEN1MAPT
SCHEMBL22773558 0.82 POLB (0.70) POLBALDH1A1KMT2AMEN1MAPT
SCHEMBL21788779 0.82 POLB (0.70) POLBALDH1A1KMT2AMEN1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642344-B2 Methods and compositions for determining the sequence of nucleic acid molecules OPERON BIOTECHNOLOGIES, INC. (US) 2010-01-05 US claimed
EP-0992511-B1 Methods and compositions for determining the sequence of nucleic acid molecules OPERON BIOTECHNOLOGIES INC (US) 2009-03-11 EP claimed
US-20080009613-A1 Methods and compositions for determining the sequence of nucleic acid molecules OPERON BIOTECHNOLOGIES, INC. (US) 2008-01-10 US claimed
EP-0868535-B9 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES QIAGEN GENOMICS INC (US) 2007-05-09 EP claimed
EP-0868535-B2 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES QIAGEN GENOMICS INC (US) 2006-01-04 EP claimed
CN-1163619-C Method and compositions for determining sequence of nucleic acid molecules �Ѹ�������ѧ��˾ 2004-08-25 CN claimed
CN-1515541-A Method for detecting ligand pair combination by using non-fluorescent marker and its composite ռ�˹ 2004-07-28 CN claimed
EP-0990047-B1 METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY QIAGEN GENOMICS INC (US) 2003-05-14 EP claimed
US-20030077595-A1 Methods and compositions for enhancing sensitivity in the analysis of biological-based assays QIAGEN GENOMICS, INC. 2003-04-24 US claimed
US-20020119456-A1 Methods and compositions for determining the sequence of nucleic acid molecules AGILENT TECHNOLOGIES, INC. 2002-08-29 US claimed
EP-0962464-A2 Methods and compositions for detecting binding of ligand pair using non-fluorescent label Rapigene, Inc. (US) 1999-12-08 EP claimed
WO-1999005319-A9 METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY RAPIGENE INC (US) 1999-06-17 WO claimed
CN-1212019-A Methods and compositions for detecting ligand pair binding using non-fluorescent labels RAPIGENE INC (US) 1999-03-24 CN claimed
CN-1212021-A Method and compositions for determining sequence of nucleic acid molecules RAPIGENE INC (US) 1999-03-24 CN claimed
WO-1999005319-A2 METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY RAPIGENE, INC. (US) 1999-02-04 WO claimed
EP-0868535-A2 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES Rapigene, Inc. (US) 1998-10-07 EP claimed
EP-0850320-A2 METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL DARWIN MOLECULAR CORPORATION (US) 1998-07-01 EP claimed
WO-1997027331-A9 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES 1997-10-09 WO claimed
WO-1997027331-A2 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES RAPIGENE, INC. (US) 1997-07-31 WO claimed
WO-1997027327-A2 METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL RAPIGENE, INC. (US) 1997-07-31 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009613-A1 Methods and compositions for determining the sequence of nucleic acid molecules CPSF6, RNMT, POLM POLB 68/4885ALDH1A1 3332/4885KMT2A 1215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.